Tuesday, October 23, 2007

Mesothelioma Alerts

Mesothelioma Subtype Shows Lengthier Projected Longevity: IASLC

By Charles Bankhead, Staff Writer, MedPage Today
September 21, 2007

Some malignant mesothelioma patients may have a prognosis that's not as grim as once widely believed, said a Nordic collaborative group
ASCO: Recent Study Confirms Pemetrexed-Platinum Activity in Malignant Mesothelioma

By Peggy Peck, Managing Editor, MedPage Today
June 06, 2007

Confirming results of previous studies, pemetrexed combined with either cisplatin or carboplatin demonstrated activity in previously untreated malignant pleural mesothelioma, said researchers.
Chemo Combination Improves Survival in Asbestos-Related Cancer

By Lise Millay Stevens, Contributing Writer, Health Behavior News Service February 8, 2007

People with mesothelioma — a form of cancer associated with asbestos exposure — have a higher survival rate when treated with a combination of two cancer drugs, a large multicenter study finds.
Onconase Shows Unique Promise In Treating Mesothelioma

RTT News June 27, 2006

Alfacell Corp. said that according to the research findings published in National Academy of Sciences Journal, the company's anti-cancer drug Onconase might be one of the most effective methods of treatment for mesothelioma and lung cancer caused by asbestos.
FDA approves Alimta-Cisplatin Combination for treatment of Asbestos-Related Cancer

Press Release February 2, 2004

The first and only drug regimen proven to help patients with an asbestos-related cancer live longer was approved today by the U.S. Food and Drug Administration.
Experimental Cancer Drug Tarceva

Reuters October 9, 2002

OSI Pharmaceuticals Inc. is more confident than ever of the potential of its experimental cancer drug Tarceva (erlotinib HCl), even after the failure of a similar drug in a major clinical study this summer, OSI Chairman and CEO Dr. Colin Goddard told investors at the UBS Warburg Global Life Sciences conference here on Wednesday.


No comments: